Efficacy and safety of LixiLan, a fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes not adequately controlled on basal insulin: LixiLan-L trial

被引：0
|
作者：
Aroda, V. R. [1 ]
Rosenstock, J. [2 ]
Wysham, C. [3 ]
Unger, J. [4 ]
Bellido, D. [5 ]
Galvez, G. Gonzalez [6 ]
Takami, A. [7 ]
Guo, H. [8 ]
Niemoeller, E. [9 ]
Souhami, E. [10 ]
Bergenstal, R. M. [11 ]
机构：
[1] Medstar Hlth Res Inst, Hyattsville, MD USA
[2] Dallas Diabet & Endocrine Ctr Med City, Dallas, TX USA
[3] Rockwood Clin, Spokane, WA USA
[4] Catalina Res Inst, Chino, CA USA
[5] Complejo Hosp Univ Ferrol, La Coruna, Spain
[6] Inst Jalisci Invest Diabet & Obesidad SC, Guadalajara, Jalisco, Mexico
[7] Sanofi, Tokyo, Japan
[8] BMD Consulting Inc, Somerset, NJ USA
[9] Sanofi, Frankfurt, Germany
[10] Sanofi, Paris, France
[11] Int Diabet Ctr, Minneapolis, MN USA
来源：
DIABETOLOGIA | 2016年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4
引用
收藏
页码：S2 / S3
页数：2
相关论文
共 50 条
  • [1] Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial
    Aroda, Vanita R.
    Rosenstock, Julio
    Wysham, Carol
    Unger, Jeffrey
    Bellido, Diego
    Gonzalez-Galvez, Guillermo
    Takami, Akane
    Guo, Hailing
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Bergenstal, Richard M.
    DIABETES CARE, 2016, 39 (11) : 1972 - 1980
  • [2] Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial (vol 39, pg 1972, 2016)
    Aroda, Vanita R.
    Rosenstock, Julio
    Wysham, Carol
    Unger, Jeffrey
    Bellido, Diego
    Gonzalez-Galvez, Guillermo
    Takami, Akane
    Guo, Hailing
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Bergenstal, Richard M.
    DIABETES CARE, 2017, 40 (06) : 809 - 809
  • [3] Postprandial glycaemic outcomes of a fixed-ratio combination of insulin glargine and lixisenatide in the LixiLan-L trial
    Vidal, J.
    Giorgino, F.
    Stager, W.
    Nikonova, E. V.
    Vlajnic, A.
    Perfetti, R.
    Meier, J.
    DIABETOLOGIA, 2016, 59 : S382 - S383
  • [4] Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial
    Rosenstock, Julio
    Diamant, Michaela
    Aroda, Vanita R.
    Silvestre, Louise
    Souhami, Elisabeth
    Zhou, Tianyue
    Perfetti, Riccardo
    Fonseca, Vivian
    DIABETES CARE, 2016, 39 (09) : 1579 - 1586
  • [5] Outcomes of LixiLan, a fixed-ratio combination of insulin glargine/lixisenatide, versus insulin glargine and lixisenatide by baseline characteristics: LixiLan-O trial
    Guerci, B.
    Davies, M.
    Leiter, L. A.
    Grunberger, G.
    Ampudia-Blasco, F.
    Yu, C.
    Stager, W.
    Niemoeller, E.
    Souhami, E.
    Rosenstock, J.
    DIABETOLOGIA, 2016, 59 : S384 - S384
  • [6] Clinical impact of LixiLan, a fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on oral agents: LixiLan-O trial
    Rosenstock, J.
    Aronson, R.
    Hanefeld, M.
    Piatti, P.
    Serusclat, P.
    Cheng, X.
    Zhou, T.
    Niemoeller, E.
    Souhami, E.
    Grunberger, G.
    Davies, M.
    DIABETOLOGIA, 2016, 59 : S384 - S385
  • [7] Efficacy and safety of the insulin glargine/lixisenatide fixed-ratio combination versus insulin glargine in patients with T2DM: the LixiLan-L trial (NCT02058160).
    Aroda, Vanita
    Rosenstock, Julio
    Wysham, Carol
    Unger, Jeffrey
    Bellido, Diego
    Gonzalez-Galvez, Guillermo
    Guo, Hailing
    Takami, Akane
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Bergenstal, Richard
    PHARMACOTHERAPY, 2016, 36 (12): : E231 - E231
  • [8] Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial
    Rosenstock, Julio
    Aronson, Ronnie
    Grunberger, George
    Hanefeld, Markolf
    Piatti, PierMarco
    Serusclat, Pierre
    Cheng, Xi
    Zhou, Tianyue
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Davies, Melanie
    DIABETES CARE, 2016, 39 (11) : 2026 - 2035
  • [9] Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial
    Lawrence Blonde
    Timothy S. Bailey
    Jason Chao
    Terry A. Dex
    Juan Pablo Frias
    Luigi F. Meneghini
    Michelle Roberts
    Vanita R. Aroda
    Advances in Therapy, 2019, 36 : 2310 - 2326
  • [10] Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial
    Blonde, Lawrence
    Bailey, Timothy S.
    Chao, Jason
    Dex, Terry A.
    Frias, Juan Pablo
    Meneghini, Luigi F.
    Roberts, Michelle
    Aroda, Vanita R.
    ADVANCES IN THERAPY, 2019, 36 (09) : 2310 - 2326
12345